Clinical Trial Update: LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib [Phase 3]

View source ↗

Summary

Phase 3 trial comparing LDK378 (alectinib) to chemotherapy in ALK-rearranged non-small cell lung cancer patients previously treated with platinum doublet and cr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• LDK378 (Alectinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2017-07-27